GLP-1 Drugs Appear To Lower Cancer Risk

Follow Drugslib on

Medically reviewed by Drugs.com.

By Dennis Thompson HealthDay Reporter

MONDAY, May 19, 2025 — Cutting-edge GLP-1 weight-loss drugs appear to help lower cancer risk even beyond the benefits from dropping excess pounds, a new study says.

First-generation GLP-1 drugs like liraglutide (Saxenda) and exenatide (Byetta) were associated with a 41% lower risk of obesity-related cancers, compared with weight-loss surgery, researchers report in the journal eClinicalMedicine.

“We do not yet fully understand how GLP-1s work, but this study adds to the growing evidence showing that weight loss alone cannot completely account for the metabolic, anti-cancer, and many other benefits that these medications provide,” lead researcher Dr. Yael Wolff Sagy from Clalit Health Services in Tel-Aviv, Israel, said in a news release.

Newer generation, highly potent GLP-1 drugs like Ozempic and Zepbound might even convey a greater advantage in reducing cancer risk, but they weren’t studied in this report, researchers said.

Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.

For the new study, researchers tracked electronic health record data for more than 6,300 people 24 and older. All had obesity and type 2 diabetes and were treated with first-generation GLP-1 drugs or underwent weight-loss surgery between 2010 and 2018.

Obesity and diabetes are both associated with an increased risk for many types of cancer, including breast, colon, uterus, liver, pancreatic, thyroid, stomach and ovarian cancers, researchers said in background notes.

Patients were followed until December 2023 to see if any developed cancer. During an average follow-up of 7.5 years, nearly 300 developed obesity-related cancer.

The most common cancers were breast (26%); colon (16%); and uterus (15%).

Even though weight-loss surgeries cause greater weight loss and are known to reduce cancer risk, roughly as many cases of cancer developed among people taking GLP-1 drugs, results show.

Further analysis showed that GLP-1 drugs had a direct effect on reducing cancer risk, with a 41% lower risk compared to surgery.

“The protective effects of GLP-1 (drugs) against obesity-related cancers likely arise from multiple mechanisms, including reducing inflammation,” said co-lead researcher Dr. Dror Dicker. He heads the obesity clinic at Hasharon Hospital-Rabin Medical Center at Petah Tikva, Israel.

“New generation, highly potent GLP-1 [drugs] with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers, but future research is needed to make sure that these drugs do not increase the risk for non-obesity-related cancers,” he added in a news release.

Sources

  • European Association for the Study of Obesity, news release, May 11, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-05-20 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords